NEW YORK, NY / ACCESSWIRE / September 20, 2022 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sotera Health Company ("Sotera" or the "Company) (NASDAQ:SHC). Investors who purchased Sotera securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/shc.
The investigation concerns whether Sotera and certain of its officers and/or directors have violated federal securities laws.
On September 19, 2022, news outlets reported that a jury found Sotera's Sterigenics business unit liable for a role in causing a woman's breast cancer and awarded the plaintiff $363 million. The lawsuit specifically alleged that carcinogenic emissions from a Sterigenics plant near the plaintiff's home caused her cancer. On this news, Sotera's stock price fell $4.90 per share, or 33.27%, to close at $9.83 per share on September 19, 2022.
If you are aware of any facts relating to this investigation or purchasedSotera shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/shc. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC represents investors in securities fraud class actions and shareholder derivative suits. The firm has recovered hundreds of millions of dollars for investors nationwide. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Nathanson
212-697-6484 | [email protected]
SOURCE: Bronstein, Gewirtz & Grossman, LLC